GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » EBITDA Margin %

Biosyent (Biosyent) EBITDA Margin % : 24.08% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Biosyent EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biosyent's EBITDA for the three months ended in Dec. 2023 was $1.49 Mil. Biosyent's Revenue for the three months ended in Dec. 2023 was $6.17 Mil. Therefore, Biosyent's EBITDA margin for the quarter that ended in Dec. 2023 was 24.08%.


Biosyent EBITDA Margin % Historical Data

The historical data trend for Biosyent's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent EBITDA Margin % Chart

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.22 26.15 31.17 28.50 28.67

Biosyent Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.47 26.64 26.96 35.97 24.08

Competitive Comparison of Biosyent's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Biosyent's EBITDA Margin % falls into.



Biosyent EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Biosyent's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=6.752/23.547
=28.67 %

Biosyent's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=1.485/6.167
=24.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyent  (OTCPK:BIOYF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Biosyent EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Biosyent's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (Biosyent) Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (Biosyent) Headlines

From GuruFocus

BioSyent Announces Approval of New Product

By GlobeNewswire GlobeNewswire 05-31-2023

BioSyent Declares Second Quarter 2023 Dividend

By GlobeNewswire GlobeNewswire 05-25-2023

BioSyent Initiates First Dividend

By GlobeNewswire GlobeNewswire 10-12-2022

When Being Certain Isn't Enough

By Thomas Macpherson Thomas Macpherson 08-30-2019

BioSyent Announces Changes to Executive Management

By GlobeNewswire GlobeNewswire 09-10-2018

BioSyent Announces Grant of Restricted Share Units

By GlobeNewswire GlobeNewswire 03-31-2023

BioSyent to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 04-25-2018

BioSyent to Present at The LD 500 Virtual Conference

By ACCESSWIRE ACCESSWIRE 08-25-2020